Fesoterodine
Chemical compound / From Wikipedia, the free encyclopedia
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007,[2] the US Food and Drug Administration on October 31, 2008 [3] and Health Canada on February 9, 2012.[4]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Toviaz |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609021 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 52% (active metabolite) |
Protein binding | 50% (active metabolite) |
Metabolism | Liver (CYP2D6- and 3A4-mediated) |
Elimination half-life | 7–8 hours (active metabolite) |
Excretion | Kidney (70%) and fecal (7%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.184.854 |
Chemical and physical data | |
Formula | C26H37NO3 |
Molar mass | 411.586 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.